Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Public-Private Confab Set for November 16; Pro-Innovation Measures Up for Discussion
November 10, 2020
- Japan to Set New Technical Fee for CureApp’s Quit Smoking App
November 10, 2020
- MHLW Unveils Draft Ordinance for Electronic Distribution of Package Inserts; Use of GS1 Codes Expected
November 10, 2020
- Swiftly Disclose PAFSC Minutes for COVID-19 Vaccines: Opposition Parties
November 9, 2020
- MHLW to Appropriately Handle FY2021 Off-Year Re-Pricing Debate: Minister
November 9, 2020
- MHLW Won’t Exclude Software Programs from Conditional Approval Coverage: Official
November 6, 2020
- Bill to Amend Immunization Act to Enter Lower House Deliberations on November 10
November 6, 2020
- Package Insert Revisions Ordered for Opdivo, Copaxone
November 6, 2020
- Japan Trade Groups Renew Call for Cautious Discussions on Off-Year Re-Pricing: LDP Policy Confab
November 5, 2020
- LDP’s Fiscal Consolidation Panel Calls for Full Implementation of Off-Year Re-Pricing: Interim Report
November 5, 2020
- Ryukaikon Confab Finally Set for November 24; Can Japan Improve Drug Distribution Environment Again?
November 4, 2020
- Working Group Agrees to Designate 10-20 “Stable Supply Medicines” as Top Priority Drugs
November 4, 2020
- Health Minister Stresses Importance of Japan-Made Vaccines Too
November 4, 2020
- Sakigake-Designated HAE Med Berotralstat, AZ’s Acalabrutinib Clear PAFSC Review
November 2, 2020
- MHLW to Introduce Vaccination Facilitation System for Wholesalers, Medical Institutions
November 2, 2020
- OxyContin Gets Delayed Approval in Japan with Special Distribution Scheme Now in Place
October 30, 2020
- MHLW’s Switch OTC Panel to Take on Mere Advisory Role in Line with Govt’s Policy
October 30, 2020
- Forxiga’s Heart Failure Use Now in Line for November Approval, Covers HFrEF Patients
October 30, 2020
- Japan to Receive 50 Million Doses of Moderna COVID-19 Vaccines via Takeda
October 29, 2020
- Chuikyo Reps Agree on Need to Validate Current Cost-Effectiveness Analysis Scheme
October 29, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…